Enlivex (ENLV) Non-Current Assets (2013 - 2025)
Enlivex (ENLV) posted quarterly Non-Current Assets of $583.8 million for Q4 2025, up 34363.99% year-over-year from N/an in Q4 2024, and up 40443.06% quarter-over-quarter from $1.4 million in Q3 2025.
Enlivex (ENLV) Non-Current Assets (2013 - 2025) Analysis & Trends
Enlivex's Non-Current Assets history runs 13 years deep, the most recent figure standing at $583.8 million for Q4 2025.
- In Q4 2025, Non-Current Assets rose 34363.99% year-over-year to $583.8 million; the TTM figure through Dec 2025 stood at $583.8 million (up 34363.99% YoY), while the FY2025 annual figure was $583.8 million, up 34363.99% from the prior year.
- Non-Current Assets for Q4 2025 stood at $583.8 million, up from $1.4 million in the prior quarter.
- The five-year high for Non-Current Assets was $583.8 million in Q4 2025, with the low at $1.3 million in Q2 2025.
- The 5-year median for Non-Current Assets is $5.6 million (2021), against an average of $36.6 million.
- The sharpest annual moves came in 2024 and 2025: Non-Current Assets plunged 88.1% in 2024, then surged 34363.99% in 2025.
- Enlivex's Non-Current Assets stood at $8.7 million in 2021, then soared by 75.92% to $15.3 million in 2022, then tumbled by 79.97% to $3.1 million in 2023, then plunged by 44.77% to $1.7 million in 2024, then soared by 34363.99% to $583.8 million in 2025.
- Business Quant data shows ENLV's Non-Current Assets at $583.8 million in Q4 2025, $1.4 million in Q3 2025, and $1.3 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.41 Bn | 131.56 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 86.14 Bn | 78.15 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 65.52 Bn | 60.34 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 58.21 Bn | 53.07 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 42.15 Bn | 37.05 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 27.95 Bn | 9.56 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.30 Bn | 26.46 Bn | - | 18.06 Bn |
| 10 | Enlivex | 4.50 Mn | -1.25 Mn | - | 583.82 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 583.82 Mn |
| Sep 30, 2025 | 1.44 Mn |
| Jun 30, 2025 | 1.27 Mn |
| Mar 31, 2025 | 1.39 Mn |
| Dec 31, 2024 | 1.69 Mn |
| Sep 30, 2024 | 2.69 Mn |
| Jun 30, 2024 | 3.33 Mn |
| Mar 31, 2024 | 2.67 Mn |
| Dec 31, 2023 | 3.07 Mn |
| Sep 30, 2023 | 15.10 Mn |
| Jun 30, 2023 | 22.24 Mn |
| Mar 31, 2023 | 22.44 Mn |
| Dec 31, 2022 | 15.31 Mn |
| Sep 30, 2022 | 13.18 Mn |
| Jun 30, 2022 | 12.29 Mn |
| Mar 31, 2022 | 9.32 Mn |
| Dec 31, 2021 | 8.70 Mn |
| Sep 30, 2021 | 7.89 Mn |
| Jun 30, 2021 | 2.36 Mn |
| Mar 31, 2021 | 2.19 Mn |